IMMUTEP Ltd (PRRUF)
OTC Markets
Key stats Fiscal year 2025
Income statement
- Revenue
- 10,331,373 31.8%
- Net income
- -61,434,165
- Earnings per share
- -0.04
- R&D expense
- 49,778,916
Growth and profitability
- Net margin
- -594.64
- Return on equity
- -42.77
- Return on assets
- -39.13
- Free cash flow margin
- -601.04
Balance sheet
- Total assets
- 156,983,434
- Total liabilities
- 13,348,071
- Shareholders' equity
- 143,635,363
- Cash and equivalents
- 67,408,215
- Current ratio
- 11.69
Cash flow and ratios
- Operating cash flow
- -62,049,706
- Free cash flow
- -62,095,475
Shareholder returns
- Shares outstanding
- 1,473,721,306
- Book value per share
- 0.10
Company information
- Headquarters
- Sydney,, C3
- Exchange
- OTC Markets
- Fiscal year end
- 06-30
- Industry (SEC)
- Pharmaceutical Preparations
Fiscal year end: · Source: SEC EDGAR
IMMUTEP Ltd trades on OTC Markets under the ticker symbol PRRUF. This page brings together its price chart, company profile, key financial figures and technical indicators.